Nektar Therapeutics Company Profile (NASDAQ:NKTR)

About Nektar Therapeutics (NASDAQ:NKTR)

Nektar Therapeutics logoNektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company's research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates. These drug candidates utilize its polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Its programs include Immuno-oncology (I-O), Immunology, Pain-NKTR-181 and Oncology-ONZEALD. It is developing medicines designed to directly or indirectly modulate the activity of key immune cells, such as cytotoxic T cells and Natural Killer (NK) cells, to increase their numbers and improve their function to recognize and attack cancer cells.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:NKTR
  • CUSIP: 64026810
  • Web:
  • Market Cap: $3.7 billion
  • Outstanding Shares: 156,328,000
Average Prices:
  • 50 Day Moving Avg: $22.80
  • 200 Day Moving Avg: $20.43
  • 52 Week Range: $11.41 - $25.02
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -21.52
  • P/E Growth: 3.22
Sales & Book Value:
  • Annual Revenue: $133.1 million
  • Price / Sales: 27.80
  • Book Value: $0.02 per share
  • Price / Book: 1,183.50
  • EBITDA: ($154,130,000.00)
  • Net Margins: -157.14%
  • Return on Equity: -1,223.34%
  • Return on Assets: -41.87%
  • Debt-to-Equity Ratio: 72.60%
  • Current Ratio: 3.97%
  • Quick Ratio: 3.82%
  • Average Volume: 1.19 million shs.
  • Beta: 1.48
  • Short Ratio: 10.01

Frequently Asked Questions for Nektar Therapeutics (NASDAQ:NKTR)

What is Nektar Therapeutics' stock symbol?

Nektar Therapeutics trades on the NASDAQ under the ticker symbol "NKTR."

How were Nektar Therapeutics' earnings last quarter?

Nektar Therapeutics (NASDAQ:NKTR) released its earnings results on Tuesday, August, 8th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by $0.04. The firm had revenue of $34.60 million for the quarter, compared to analyst estimates of $33.64 million. Nektar Therapeutics had a negative return on equity of 1,223.34% and a negative net margin of 157.14%. Nektar Therapeutics's revenue was up 5.5% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.36) earnings per share. View Nektar Therapeutics' Earnings History.

When will Nektar Therapeutics make its next earnings announcement?

Nektar Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, November, 2nd 2017. View Earnings Estimates for Nektar Therapeutics.

Where is Nektar Therapeutics' stock going? Where will Nektar Therapeutics' stock price be in 2017?

10 brokers have issued 1 year price targets for Nektar Therapeutics' stock. Their forecasts range from $20.00 to $33.00. On average, they expect Nektar Therapeutics' share price to reach $27.11 in the next year. View Analyst Ratings for Nektar Therapeutics.

What are analysts saying about Nektar Therapeutics stock?

Here are some recent quotes from research analysts about Nektar Therapeutics stock:

  • 1. Mizuho analysts commented, "We like the company for its immuno-oncology candidate NKTR-214, which could provide significant upside while the broad, royalty-generating portfolio helps smooth the revenue lumpiness a biotech company faces." (9/26/2017)
  • 2. According to Zacks Investment Research, "Nektar reported wider-than-expected loss in the second quarter of 2017 with revenue missing estimates. The launch of its drugs, Movantik and Adynovate, has been on track with both the products performing impressively. Additionally, regular partnerships have enhanced the company’s financial position. Nektar stands to receive significant sales milestone plus royalties for Movantik under the license agreement with AstraZeneca, which might substantially boost its financial position. Also, its recent co-development deal with Lilly for NKTR-358 is also encouraging. However, Nektar relies heavily on partners for revenues. Partnership-related setbacks may weigh heavily on the company, while disappointing products sales could leave an adverse impact on its financial results. Nektar also has a promising pipeline, with several updates lined up for the next several quarters. The company’s shares have outperformed the industry in the year so far." (8/11/2017)
  • 3. BTIG Research analysts commented, "Nektar announced positive results from the Phase 3 SUMMIT-07 study of NKTR-181, its novel, proprietary, abuse-resistant opioid for pain. NKTR- 181 met all important primary and secondary efficacy endpoints in the 610- patient study, and the molecule appeared well tolerated, materially derisking the program. At its primary endpoint at week 12 postrandomization, average pain scores increased 1.46 points on the Numeric Rating Scale with placebo, vs. 0.92 points for NKTR-181 (p=0.0019); other secondary endpoints were also as positive. NKTR-181 has been FastTracked, a rarity for an opioid, and with this highly positive study in hand, there is a possibility for rapid progression of NKTR-181, and a material partnership. With 181's success, and with the potential for additional meaningful catalysts near-term, we raise our NKTR price target to $27." (3/21/2017)
  • 4. Jefferies Group LLC analysts commented, "The unexpected Ph 3 success for '181 brings this once very promising mu-opioid analgesic asset back to life. In our view, it could become NKTR's largest and most profitable product as it squarely addresses the 'opioid epidemic'. Mgt hopes to partner the drug by YE. We believe '181 could bring significant value (modeling 30% royalties and $250M+ in milestones) to the company as early as 2020. With this asset now unencumbered, NKTR now fits our M&A thesis." (3/21/2017)
  • 5. Aegis analysts commented, "NKTR-181 met its primary endpoint in the phase III Summit-07 trial - increase Price Target to $25. Yesterday morning, Netkar Therapeutics announced that NKTR-181 met its primary endpoint of mean change in weekly average numeric rating scale (NRS) pain score for the randomized, double-blind treatment period from the end of the open-label titration period (baseline) to week 12. Average pain scores measured at week 12 from baseline increased 1.46 for placebo vs. 0.92 for NKTR-181 (p=0.0019). We had not previously factored in revenue from NKTR-181 into our price target. As a result of the positive phase III results, we now include such revenue under partnering assumptions in the US and raise our price target from $21 to $24." (3/20/2017)

Who are some of Nektar Therapeutics' key competitors?

Who are Nektar Therapeutics' key executives?

Nektar Therapeutics' management team includes the folowing people:

  • Robert B. Chess, Independent Chairman of the Board
  • Howard W. Robin, President, Chief Executive Officer, Director
  • Gilbert M. Labrucherie J.D., Chief Financial Officer, Senior Vice President
  • John L. Nicholson, Chief Operating Officer, Senior Vice President
  • Jillian B. Thomsen, Senior Vice President - Finance, Chief Accounting Officer
  • Stephen K. Doberstein Ph.D., Senior Vice President, Chief Scientific Officer
  • Ivan Philip Gergel M.D., Senior Vice President - Drug Development & Chief Medical Officer
  • Maninder Hora Ph.D., Senior Vice President - Pharmaceutical Development and Manufacturing Operations
  • Jeff Robert Ajer, Independent Director
  • R. Scott Greer, Independent Director

How do I buy Nektar Therapeutics stock?

Shares of Nektar Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Nektar Therapeutics' stock price today?

One share of Nektar Therapeutics stock can currently be purchased for approximately $23.67.

MarketBeat Community Rating for Nektar Therapeutics (NASDAQ NKTR)
Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  337 (Vote Outperform)
Underperform Votes:  134 (Vote Underperform)
Total Votes:  471
MarketBeat's community ratings are surveys of what our community members think about Nektar Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Nektar Therapeutics (NASDAQ:NKTR) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 9 Buy Ratings
Consensus Rating:Buy (Score: 2.90)
Consensus Price Target: $27.11 (14.54% upside)
Consensus Price Target History for Nektar Therapeutics (NASDAQ:NKTR)
Price Target History for Nektar Therapeutics (NASDAQ:NKTR)
Analysts' Ratings History for Nektar Therapeutics (NASDAQ:NKTR)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/26/2017MizuhoInitiated CoverageBuy$30.00HighView Rating Details
8/18/2017Jefferies Group LLCReiterated RatingBuy$23.00LowView Rating Details
8/17/2017Evercore ISIInitiated CoverageIn -> In-Line$20.00HighView Rating Details
8/9/2017Roth CapitalSet Price TargetBuy$33.00HighView Rating Details
8/7/2017HC WainwrightInitiated CoverageBuy -> Buy$31.00LowView Rating Details
7/18/2017William BlairReiterated RatingOutperformLowView Rating Details
5/10/2017AegisReiterated RatingBuy$27.00HighView Rating Details
4/11/2017Piper Jaffray CompaniesReiterated RatingOverweight$29.00LowView Rating Details
3/21/2017BTIG ResearchBoost Price TargetPositive$22.00 -> $27.00MediumView Rating Details
3/21/2017J P Morgan Chase & CoSet Price TargetBuy$24.00MediumView Rating Details
9/30/2016Brean CapitalReiterated RatingBuy$23.00N/AView Rating Details
1/27/2016Janney Montgomery ScottInitiated CoverageBuy$21.00N/AView Rating Details
(Data available from 10/20/2015 forward)


Earnings History for Nektar Therapeutics (NASDAQ:NKTR)
Earnings by Quarter for Nektar Therapeutics (NASDAQ:NKTR)
Earnings History by Quarter for Nektar Therapeutics (NASDAQ NKTR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2017Q2 2017($0.35)($0.39)$33.64 million$34.60 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.40)($0.42)$29.43 million$24.73 millionViewListenView Earnings Details
3/1/2017Q416($0.26)($0.28)$40.83 million$37.45 millionViewListenView Earnings Details
11/3/2016Q316($0.36)($0.32)$32.42 million$36.30 millionViewN/AView Earnings Details
8/3/2016Q216($0.33)($0.36)$34.17 million$32.77 millionViewListenView Earnings Details
5/3/2016Q1($0.23)($0.14)$43.78 million$58.88 millionViewN/AView Earnings Details
3/1/2016Q4($0.42)($0.40)$28.82 million$39.40 millionViewListenView Earnings Details
11/5/2015Q315($0.30)($0.06)$44.30 million$60.00 millionViewN/AView Earnings Details
8/5/2015Q215($0.40)($0.40)$21.49 million$22.66 millionViewN/AView Earnings Details
4/30/2015Q115($0.40)$0.25$20.20 million$108.80 millionViewN/AView Earnings Details
2/24/2015Q414($0.36)($0.35)$12.30 million$19.55 millionViewN/AView Earnings Details
11/6/2014Q314$0.39$0.53$123.20 million$132.90 millionViewN/AView Earnings Details
7/31/2014Q214($0.38)($0.26)$19.76 million$28.50 millionViewListenView Earnings Details
5/7/2014Q114($0.35)($0.37)$38.68 million$19.80 millionViewListenView Earnings Details
2/26/2014Q413($0.17)($0.41)$49.26 million$31.15 millionViewN/AView Earnings Details
11/7/2013Q313($0.22)($0.14)$54.34 million$60.91 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.44)($0.37)$26.22 million$33.86 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.42)($0.48)$26.30 million$23.00 millionViewN/AView Earnings Details
11/9/2012Q312($0.39)($0.38)$21.02 million$18.41 millionViewN/AView Earnings Details
8/9/2012($0.33)($0.30)ViewN/AView Earnings Details
5/2/2012($0.33)($0.36)ViewN/AView Earnings Details
2/29/2012($0.47)($0.33)ViewN/AView Earnings Details
11/2/2011($0.37)($0.21)ViewN/AView Earnings Details
8/4/2011($0.31)($0.32)ViewN/AView Earnings Details
4/27/2011($0.27)($0.33)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Nektar Therapeutics (NASDAQ:NKTR)
2017 EPS Consensus Estimate: ($0.85)
2018 EPS Consensus Estimate: ($1.12)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.49)($0.31)($0.40)
Q2 20172($0.37)($0.29)($0.33)
Q3 20172$0.15$0.27$0.21
Q4 20173($0.44)($0.18)($0.33)
Q1 20182($0.38)($0.12)($0.25)
Q2 20182($0.37)($0.13)($0.25)
Q3 20182($0.37)($0.13)($0.25)
Q4 20181($0.37)($0.37)($0.37)
(Data provided by Zacks Investment Research)


Dividend History for Nektar Therapeutics (NASDAQ:NKTR)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Nektar Therapeutics (NASDAQ:NKTR)
Insider Ownership Percentage: 6.10%
Institutional Ownership Percentage: 95.08%
Insider Trades by Quarter for Nektar Therapeutics (NASDAQ:NKTR)
Institutional Ownership by Quarter for Nektar Therapeutics (NASDAQ:NKTR)
Insider Trades by Quarter for Nektar Therapeutics (NASDAQ:NKTR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/9/2017Howard W RobinCEOSell83,333$24.20$2,016,658.60View SEC Filing  
10/5/2017Stephen K DobersteinSVPSell43,677$24.97$1,090,614.69View SEC Filing  
10/2/2017Gil M. LabrucherieCFOSell120,000$24.45$2,934,000.00View SEC Filing  
10/2/2017Ivan P GergelSVPSell100,000$24.14$2,414,000.00View SEC Filing  
9/22/2017Christopher A KueblerDirectorSell4,000$21.86$87,440.00View SEC Filing  
9/21/2017Robert ChessDirectorSell6,400$21.72$139,008.00View SEC Filing  
9/6/2017Howard W RobinCEOSell83,333$21.54$1,794,992.82View SEC Filing  
8/16/2017Howard W RobinCEOSell91,714$19.26$1,766,411.64View SEC Filing  
8/16/2017Jillian B. ThomsenCAOSell2,648$19.32$51,159.36View SEC Filing  
8/16/2017John NicholsonCOOSell3,177$19.32$61,379.64View SEC Filing  
8/16/2017Stephen K DobersteinSVPSell1,701$19.32$32,863.32View SEC Filing  
8/10/2017Roy A WhitfieldDirectorBuy35,000$17.95$628,250.00View SEC Filing  
7/18/2017Ivan P GergelSVPSell54,920$21.10$1,158,812.00View SEC Filing  
7/14/2017Lutz LingnauDirectorSell30,000$20.76$622,800.00View SEC Filing  
7/12/2017Ivan P GergelSVPSell45,080$21.08$950,286.40View SEC Filing  
7/11/2017Ivan P GergelSVPSell8,389$21.04$176,504.56View SEC Filing  
5/16/2017Gil M. LabrucherieCFOSell3,179$19.55$62,149.45View SEC Filing  
5/16/2017Howard W RobinCEOSell8,388$19.55$163,985.40View SEC Filing  
5/16/2017John NicholsonCOOSell3,146$19.55$61,504.30View SEC Filing  
5/16/2017Stephen K DobersteinSVPSell1,701$19.55$33,254.55View SEC Filing  
5/15/2017Robert ChessDirectorSell5,000$19.79$98,950.00View SEC Filing  
4/17/2017Robert ChessDirectorSell5,000$18.72$93,600.00View SEC Filing  
4/7/2017Lutz LingnauDirectorSell7,000$20.05$140,350.00View SEC Filing  
4/5/2017Christopher A KueblerDirectorSell15,000$21.88$328,200.00View SEC Filing  
4/5/2017Maninder HoraSVPSell180,000$21.70$3,906,000.00View SEC Filing  
3/20/2017Jillian B. ThomsenSVPSell112,500$19.69$2,215,125.00View SEC Filing  
3/3/2017Gil M. LabrucherieCFOSell200,000$15.16$3,032,000.00View SEC Filing  
2/16/2017Gil M. LabrucherieCFOSell2,359$13.14$30,997.26View SEC Filing  
2/16/2017Howard W RobinCEOSell8,636$13.14$113,477.04View SEC Filing  
2/16/2017Ivan P GergelSVPSell1,457$13.14$19,144.98View SEC Filing  
2/16/2017John NicholsonCOOSell3,237$13.14$42,534.18View SEC Filing  
2/8/2017Howard W RobinCEOSell87,500$13.04$1,141,000.00View SEC Filing  
2/3/2017John NicholsonCOOSell75,000$12.39$929,250.00View SEC Filing  
1/17/2017Howard W RobinCEOSell87,500$12.35$1,080,625.00View SEC Filing  
11/17/2016Howard W RobinCEOSell93,458$13.88$1,297,197.04View SEC Filing  
10/24/2016R Scott GreerDirectorBuy15,000$13.50$202,500.00View SEC Filing  
10/4/2016Howard W. RobinCEOSell87,500$17.06$1,492,750.00View SEC Filing  
9/16/2016Christopher A. KueblerDirectorSell7,500$19.13$143,475.00View SEC Filing  
9/15/2016Robert ChessDirectorSell12,000$19.21$230,520.00View SEC Filing  
9/1/2016Howard W. RobinCEOSell87,500$17.83$1,560,125.00View SEC Filing  
8/16/2016Gil M. LabrucherieCFOSell3,305$17.56$58,035.80View SEC Filing  
8/16/2016Howard W. RobinCEOSell11,817$17.56$207,506.52View SEC Filing  
8/16/2016John NicholsonCOOSell3,317$17.56$58,246.52View SEC Filing  
8/16/2016Stephen K. DobersteinSVPSell1,336$17.56$23,460.16View SEC Filing  
8/1/2016Robert ChessDirectorSell5,000$17.26$86,300.00View SEC Filing  
7/11/2016Jillian B ThomsenCAOSell100,000$15.09$1,509,000.00View SEC Filing  
7/1/2016Robert ChessDirectorSell5,000$14.10$70,500.00View SEC Filing  
5/17/2016Gil M LabrucherieSVPSell836$13.58$11,352.88View SEC Filing  
5/17/2016Howard W RobinCEOSell2,170$13.58$29,468.60View SEC Filing  
5/17/2016Jillian B ThomsenCAOSell724$13.58$9,831.92View SEC Filing  
5/17/2016John NicholsonCFOSell856$13.58$11,624.48View SEC Filing  
4/25/2016Lutz LingnauDirectorSell15,000$16.27$244,050.00View SEC Filing  
2/17/2016Howard W. RobinCEOSell2,147$11.92$25,592.24View SEC Filing  
2/17/2016Jillian B. ThomsenCAOSell716$11.92$8,534.72View SEC Filing  
2/17/2016Maninder HoraSVPSell963$11.92$11,478.96View SEC Filing  
2/10/2016Gil M. LabrucherieSVPSell11,666$11.49$134,042.34View SEC Filing  
2/10/2016Howard W. RobinCEOSell66,666$11.49$765,992.34View SEC Filing  
2/10/2016Jillian B. ThomsenCAOSell15,000$11.49$172,350.00View SEC Filing  
1/20/2016Lutz LingnauDirectorSell15,000$14.51$217,650.00View SEC Filing  
1/19/2016Gil M. LabrucherieSVPSell11,667$14.12$164,738.04View SEC Filing  
1/19/2016Howard W. RobinCEOSell66,667$14.12$941,338.04View SEC Filing  
1/19/2016Jillian B. ThomsenCAOSell15,000$14.12$211,800.00View SEC Filing  
12/4/2015Christopher A. KueblerDirectorSell15,000$15.82$237,300.00View SEC Filing  
12/3/2015Gil M. LabrucherieSVPSell45,001$15.87$714,165.87View SEC Filing  
12/3/2015Howard W. RobinCEOSell125,001$15.87$1,983,765.87View SEC Filing  
12/3/2015Jillian B. ThomsenCAOSell15,000$15.87$238,050.00View SEC Filing  
11/20/2015Susan WangDirectorSell85,000$15.02$1,276,700.00View SEC Filing  
11/11/2015Gil M. LabrucherieSVPSell45,000$13.52$608,400.00View SEC Filing  
11/11/2015Howard W. RobinCEOSell125,000$13.52$1,690,000.00View SEC Filing  
11/11/2015Jillian B. ThomsenCAOSell15,000$13.52$202,800.00View SEC Filing  
10/28/2015Lutz LingnauDirectorSell12,500$12.00$150,000.00View SEC Filing  
10/6/2015Gil M. LabrucherieSVPSell45,000$10.99$494,550.00View SEC Filing  
10/6/2015Howard W. RobinCEOSell125,000$10.99$1,373,750.00View SEC Filing  
10/6/2015Jillian B. ThomsenCAOSell15,000$10.99$164,850.00View SEC Filing  
9/23/2015Gil M. LabrucherieSVPSell44,999$13.04$586,786.96View SEC Filing  
9/23/2015Howard W. RobinCEOSell124,999$13.04$1,629,986.96View SEC Filing  
9/23/2015Jillian B. ThomsenCAOSell10,000$13.04$130,400.00View SEC Filing  
8/13/2015Gil M LabrucherieSVPSell33,333$10.89$362,996.37View SEC Filing  
8/13/2015Howard W RobinCEOSell58,333$10.89$635,246.37View SEC Filing  
7/14/2015Gil M LabrucherieSVPSell33,334$11.78$392,674.52View SEC Filing  
7/14/2015Howard W RobinCEOSell58,334$11.78$687,174.52View SEC Filing  
6/29/2015Susan WangDirectorSell30,000$12.70$381,000.00View SEC Filing  
6/19/2015Robert ChessDirectorSell15,000$11.81$177,150.00View SEC Filing  
6/15/2015Lutz LingnauDirectorSell25,000$11.15$278,750.00View SEC Filing  
12/29/2014Robert ChessDirectorSell29,500$15.34$452,530.00View SEC Filing  
12/22/2014Jillian B ThomsenCAOSell5,000$15.56$77,800.00View SEC Filing  
12/1/2014Gil M LabrucherieSVPSell120,000$17.02$2,042,400.00View SEC Filing  
12/1/2014Howard W RobinCEOSell350,000$17.01$5,953,500.00View SEC Filing  
11/25/2014Howard W RobinCEOSell600,000$15.25$9,150,000.00View SEC Filing  
11/24/2014Gil M LabrucherieSVPSell10,500$15.04$157,920.00View SEC Filing  
11/24/2014Howard W RobinCEOSell132,800$15.02$1,994,656.00View SEC Filing  
11/24/2014Lutz LingnauDirectorSell15,000$15.02$225,300.00View SEC Filing  
11/3/2014Gil M LabrucherieSVPSell9,900$13.78$136,422.00View SEC Filing  
8/5/2013Roy WhitfieldDirectorSell12,500$12.41$155,125.00View SEC Filing  
9/14/2012Dennis L WingerDirectorBuy5,000$9.18$45,900.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Nektar Therapeutics (NASDAQ:NKTR)
Latest Headlines for Nektar Therapeutics (NASDAQ:NKTR)
DateHeadline logoNektar Therapeutics (NKTR) Given Consensus Recommendation of "Buy" by Brokerages - October 19 at 6:46 AM logoHead to Head Comparison: Senestech (SNES) vs. Nektar Therapeutics (NKTR) - October 17 at 8:26 AM logoBiotech Stocks on Investors' Radar -- Nektar Therapeutics, Ophthotech, PTC Therapeutics, and Spark Therapeutics - PR Newswire (press release) - October 17 at 2:35 AM logoFinancial Review: Nektar Therapeutics (NKTR) & Cleveland BioLabs (CBLI) - October 16 at 10:30 AM logoStephen K. Doberstein Sells 43,677 Shares of Nektar Therapeutics (NKTR) Stock - October 10 at 7:18 PM logoNektar Therapeutics (NKTR) CEO Howard W. Robin Sells 83,333 Shares - October 10 at 7:16 PM logo$114.14 Million in Sales Expected for Nektar Therapeutics (NKTR) This Quarter - October 9 at 8:44 AM logoNotable Friday Option Activity: NKTR, PANW, SKX - Nasdaq - October 7 at 6:34 AM logoNektar Therapeutics (NKTR) SVP Ivan P. Gergel Sells 100,000 Shares - October 3 at 10:30 PM logoNektar Therapeutics (NKTR) CFO Sells $2,934,000.00 in Stock - October 3 at 10:28 PM logoNektar's Lead Drugs Drive Growth, Partner Reliance a Woe - October 2 at 5:57 PM logoETFs with exposure to Nektar Therapeutics : September 28, 2017 - October 2 at 5:57 PM logoHead-To-Head Review: Nektar Therapeutics (NKTR) & Its Competitors - September 27 at 4:32 PM logoNektar Therapeutics (NKTR) Now Covered by Analysts at Mizuho - September 26 at 7:34 PM logoNektar Therapeutics (NKTR) Director Sells $87,440.00 in Stock - September 25 at 7:36 PM logoInsider Selling: Nektar Therapeutics (NKTR) Director Sells 6,400 Shares of Stock - September 25 at 7:16 PM logoNektar Therapeutics (NKTR) Receives Consensus Rating of "Buy" from Brokerages - September 24 at 6:48 AM logoNektar Therapeutics (NKTR) Says Seven Abstracts Accepted for Presentation at 2017 SITC - - September 22 at 8:52 AM logoNektar Therapeutics (NKTR) Appoints Jeff Ajer to Board - - September 22 at 8:52 AM logoNektar Therapeutics Announces Seven Abstracts Accepted for Presentation at 2017 Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting - September 22 at 8:52 AM logoShould You Buy Nektar Therapeutics (NKTR) Now? - September 22 at 8:52 AM logoNektar Therapeutics Appoints Biotechnology Executive Jeff Ajer as New Board Member - September 22 at 8:52 AM logoETFs with exposure to Nektar Therapeutics : September 13, 2017 - September 14 at 8:20 AM logoBRIEF-Nektar Therapeutics initiates propel clinical study - September 13 at 7:05 AM logoNektar Therapeutics Initiates PROPEL Clinical Study to Evaluate Combination of ... - September 13 at 7:05 AM logoNektar Therapeutics (NKTR) Reports Initiation of PROPEL Clinical Study to ... - September 13 at 7:05 AM logoNektar Therapeutics Initiates PROPEL Clinical Study to Evaluate Combination of NKTR-214, a CD122-Biased Agonist, with TECENTRIQ® (atezolizumab) or KEYTRUDA® (pembrolizumab) - September 13 at 7:05 AM logoNektar Therapeutics :NKTR-US: Earnings Analysis: Q2, 2017 By the Numbers : September 11, 2017 - September 12 at 6:03 AM logoSurging Earnings Estimates Signal Good News for Nektar (NKTR) - September 9 at 6:43 AM logoInsider Selling: Nektar Therapeutics (NKTR) CEO Sells 83,333 Shares of Stock - September 8 at 7:32 PM logoNektar Therapeutics (NKTR) Announces Clinical Data from Phase 3 SUMMIT-07 Study of NKTR-181 - - September 7 at 6:50 AM logoNektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 2017 Morgan Stanley Global Healthcare Conference in New York City - September 7 at 6:50 AM logoNektar Therapeutics Presents Clinical Data from Phase 3 SUMMIT-07 Study of NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2017 PAINWeek® - September 7 at 6:50 AM logoNektar Therapeutics breached its 50 day moving average in a Bullish Manner : NKTR-US : September 1, 2017 - September 2 at 6:47 AM logoNektar Therapeutics (NKTR) to Present Data from Phase 3 SUMMIT-07 Study of NKTR-181 at PAINWeek - - August 31 at 7:49 AM logoNektar Therapeutics to Present Clinical Data from Phase 3 SUMMIT-07 Study of NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at PAINWeek® - August 31 at 7:49 AM logoNektar Therapeutics Earns Relative Strength Rating Upgrade; Hits Key Benchmark - August 30 at 7:15 AM logoInsider Selling: Nektar Therapeutics (NKTR) SVP Sells 1,701 Shares of Stock - August 18 at 8:50 PM logoNektar Therapeutics (NKTR) COO John Nicholson Sells 3,177 Shares - August 18 at 8:32 PM logoJillian B. Thomsen Sells 2,648 Shares of Nektar Therapeutics (NKTR) Stock - August 18 at 8:32 PM logoNektar Therapeutics (NKTR) CEO Howard W. Robin Sells 91,714 Shares - August 18 at 7:26 PM logoNektar Therapeutics (NKTR) Rating Reiterated by Jefferies Group LLC - August 18 at 12:00 PM logoNektar Therapeutics (NKTR) Now Covered by Analysts at Evercore ISI - August 17 at 10:56 AM logoNektar Therapeutics – Value Analysis (NASDAQ:NKTR) : August 17, 2017 - August 17 at 6:14 AM logoWill Nektar's (NKTR) Candidates Enhance Growth in 2017? - August 15 at 3:22 AM logoRoy A. Whitfield Acquires 35,000 Shares of Nektar Therapeutics (NKTR) Stock - August 14 at 10:36 AM logo Brokerages Anticipate Nektar Therapeutics (NKTR) Will Announce Quarterly Sales of $103.07 Million - August 14 at 4:42 AM logoQ3 2017 Earnings Forecast for Nektar Therapeutics Issued By Jefferies Group (NASDAQ:NKTR) - August 14 at 2:30 AM logoSee what the IHS Markit Score report has to say about Nektar Therapeutics. - August 12 at 6:17 AM logoQ3 2017 Earnings Estimate for Nektar Therapeutics (NKTR) Issued By William Blair - August 11 at 10:45 AM



Nektar Therapeutics (NKTR) Chart for Friday, October, 20, 2017

This page was last updated on 10/20/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.